Pharmaceuticals company SMS Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations in Q4FY24 was Rs 248.20 crore, up 1% YoY, driven by strong demand for key APIs. PAT for Q4FY25 stood at Rs 20.31, up 18% In Q4FY25, gross margins improved to 30%, an increase of 444 bps year-on-year, driven by backward integration, product mix, and a stable pricing environment. EBITDA margins for Q4FY25 stood at 16%, up 277 bps year-on-year, and PAT margins rose to 8%. FY25 Financial Highlights: For FY25, revenue from operations reached Rs 782.75 crore, reflecting a 10% YoY growth. We witnessed healthy growth in our high-value product portfolio. PAT for FY25 stood at Rs 69.14, up by 39% For FY25, gross margin increased to 33%, EBITDA margin to 18%, and PAT margin improved to 9%. The Board has recommended a final dividend of Rs 0.4 (40%) per equity share with a face value of Rs 1 each for FY25. New Capex of Rs 250 crore to expand capacity for new products and CMO busines Commenting on the performance, P. Vamsi Krishna, Executive Director, stated: We concluded FY25 on a strong note with 39% PAT growth, driven by volume growth and margin expansion. This was made possible by the disciplined execution of our strategy over the past four years: strengthening and diversifying our product portfolio, driving operational efficiencies, and achieving cost leadership through backward integration and scale. A key milestone was the successful ramp-up of ibuprofen, positioning us among India’s leading producers. We also onboarded several large customers across our API portfolio, further strengthening long-term revenue growth. With the backward integration project completed, key APIs at the take-off stage, and a new Capex plan underway, we are entering FY26 with strong momentum and greater earnings visibility. We are also building a robust pipeline of new molecules to drive long-term growth. Result PDF